Sugi Predict

Sugi Predict / Compounds / SCHEMBL2722889

SCHEMBL2722889

SCHEMBL2722889

C[C@@H]1CN(c2ccc(N)nc2)C[C@H](C)O1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ PIK3CA P42336 3/20 0.51
▸ MTOR P42345 3/20 0.51
▸ PIK3R1 P27986 1/20 0.43
▸ CHRNB2 P17787 1/20 0.42
▸ CHRNA4 P43681 1/20 0.42
▸ CDK4 P11802 2/20 0.41
▸ CCND1 P24385 2/20 0.41
▸ CDK6 Q00534 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ ADORA1 P30542 1/20 0.40
▸ WNT3A P56704 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ DRD2 P14416 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4825445 1.00 MAPT (0.58) MAPTRAB9APIK3CAMTORPIK3R1
SCHEMBL1393583 0.84 MAPT (0.49) MAPTRAB9APIK3CAMTORCHRNB2
SCHEMBL17340556 0.83 CDK4 (0.43) MAPTRAB9APIK3CAMTORPIK3R1
SCHEMBL21698724 0.83 CDK4 (0.43) MAPTRAB9APIK3CAMTORPIK3R1
SCHEMBL4549816 0.83 CDK4 (0.43) MAPTRAB9APIK3CAMTORPIK3R1
SCHEMBL24156931 0.81 MAPT (0.60) MAPTRAB9ACHRNB2CHRNA4CDK4
SCHEMBL17796627 0.81 CHRNB2 (0.47) MAPTRAB9APIK3CAMTORPIK3R1
SCHEMBL12697195 0.81 MAPT (0.60) MAPTRAB9ACHRNB2CHRNA4CDK4
SCHEMBL19012396 0.81 MAPT (0.60) MAPTRAB9ACHRNB2CHRNA4CDK4
SCHEMBL24156692 0.80 MAPT (0.58) MAPTRAB9ACHRNB2CHRNA4CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 — — EP disclosed
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
EP-2968291-B1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION PHARMACOSMOS HOLDING AS (DK) 2025-04-16 — — EP disclosed
US-20240109906-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-8598186-B2 CDK inhibitors G1 THERAPEUTICS, INC. (US) 2013-12-03 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
EP-2632467-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2013-09-04 — — EP disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 MAPT 2057/4885RAB9A 2036/4885PIK3CA 234/4885
US-20240109906-A1 CDK INHIBITORS CDK3, CDK9, CDK6 MAPT 2057/4885RAB9A 2036/4885PIK3CA 234/4885
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION RB1, CDK4, CDKN1A MAPT 2961/4885RAB9A 2448/4885PIK3CA 686/4885
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 MAPT 3872/4885RAB9A 2394/4885PIK3CA 178/4885
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY CDK6, CCNC, MCL1 MAPT 4062/4885RAB9A 3450/4885PIK3CA 1598/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 MAPT 2057/4885RAB9A 2036/4885PIK3CA 234/4885
US-20130237544-A1 CDK INHIBITORS CDK3, CDK9, CDK6 MAPT 2057/4885RAB9A 2036/4885PIK3CA 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.